BeiGene
BGNE
#881
Rank
S$28.88 B
Marketcap
$263.10
Share price
1.71%
Change (1 day)
-0.19%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of June 2024 : S$7.44 B

According to BeiGene 's latest financial reports the company's total assets are S$7.44 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31S$7.66 B-10.35%
2022-12-31S$8.55 B-25.71%
2021-12-31S$11.51 B55.46%
2020-12-31S$7.40 B241.52%
2019-12-31S$2.16 B-29.26%
2018-12-31S$3.06 B118.95%
2017-12-31S$1.39 B138.31%
2016-12-31S$0.58 B255.28%
2015-12-31S$0.16 B133.34%
2014-12-31S$70.84 M373.89%
2013-12-31S$14.95 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
S$23.66 M-99.68%๐Ÿ‡บ๐Ÿ‡ธ USA
S$2.57 B-65.34%๐Ÿ‡บ๐Ÿ‡ธ USA